Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer

Over 90% of pancreatic cancers present mutations in KRAS, one of the most common oncogenic drivers overall. Currently, most KRAS mutant isoforms cannot be targeted directly. Moreover, targeting single RAS downstream effectors induces adaptive resistance mechanisms. We report here on the combined inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Frank, Katrin J., Mulero-Sánchez, Antonio, Berninger, Alexandra, Ruiz-Cañas, Laura, Bosma, Astrid, Görgülü, Kıvanç, Wu, Nan, Diakopoulos, Kalliope N., Kaya-Aksoy, Ezgi, Ruess, Dietrich A., Kabacaoğlu, Derya, Schmidt, Fränze, Kohlmann, Larissa, van Tellingen, Olaf, Thijssen, Bram, van de Ven, Marieke, Proost, Natalie, Kossatz, Susanne, Weber, Wolfgang A., Sainz, Bruno, Bernards, Rene, Algül, Hana, Lesina, Marina, Mainardi, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729824/
https://www.ncbi.nlm.nih.gov/pubmed/36384095
http://dx.doi.org/10.1016/j.xcrm.2022.100815

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729824/
https://www.ncbi.nlm.nih.gov/pubmed/36384095
http://dx.doi.org/10.1016/j.xcrm.2022.100815

Ejemplares similares